Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study Group.

Ito, Y; Horikoshi, N; Watanabe, T; Sasaki, Y; Tominaga, T; Okawa, T; Tabei, T; Kuraishi, Y; Tamura, K; Abe, R; Kitajima, M; Yamaguchi, S; Kobayashi, T; Koyama, H; Orita, K; Takashima, S; Nomura, Y; Ogawa, M

Ito, Y; Horikoshi, N; Watanabe, T; Sasaki, Y; Tominaga, T; Okawa, T; Tabei, T; Kuraishi, Y; Tamura, K; Abe, R; Kitajima, M; Yamaguchi, S; Kobayashi, T; Koyama, H; Orita, K; Takashima, S; Nomura, Y; Ogawa, M.

Affiliation

Ito Y; Dept. of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo.

Invest New Drugs ; 16(2): 183-90, 1998.

Article in En | MEDLINE | ID: mdl-9848584

Subject(s)

Breast Neoplasms/drug therapy; Paclitaxel/therapeutic use; Adult; Aged; Breast Neoplasms/secondary; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel/administration & dosage; Paclitaxel/adverse effects

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Paclitaxel Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Invest New Drugs Year: 1998 Document type: Article

Search on Google

XML

PubMed Links